e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.51M | -3.46M | -3.54M | -3.42M | -2.69M |
| Total Depreciation and Amortization | 127.30K | 125.40K | 171.60K | 165.60K | 136.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 195.40K | 192.50K | -834.00K | -804.60K | 132.00K |
| Change in Net Operating Assets | 661.70K | 652.10K | -156.40K | -150.90K | 452.20K |
| Cash from Operations | -2.53M | -2.49M | -4.36M | -4.21M | -1.97M |
| Capital Expenditure | -152.50K | -150.30K | -3.20K | -3.10K | -10.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 153.10K | 150.90K | 149.50K | 144.20K | 225.50K |
| Cash from Investing | 600.00 | 600.00 | 146.30K | 141.10K | 215.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -93.00K | -93.00K | -105.00K | -105.00K | -195.50K |
| Issuance of Common Stock | 7.50K | 7.50K | 11.00K | 11.00K | 6.71M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -107.80K | -106.20K | -119.10K | -114.90K | 7.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.63M | -2.60M | -4.33M | -4.18M | 6.11M |